Screening, risk assessment, and the approach to therapy in patients with prostate cancer

Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force

(2013) Kenneth Lin et al.   ANNALS OF INTERNAL MEDICINE

Biomarkers for prostate cancer detection and progression: Beyond prostate-specific antigen

(2010) D. Berney   DRUG NEWS & PERSPECTIVES

Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer

(2009) Ryuichi Mizuno et al.   BJU INTERNATIONAL

High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up

(2009) Benjamin J. Challacombe et al.   BJU INTERNATIONAL

Critical appraisal of outcomes following open radical prostatectomy

(2009) David J Galvin et al.   CURRENT OPINION IN UROLOGY

Prostate cryotherapy: current status

(2009) Chad R Ritch et al.   CURRENT OPINION IN UROLOGY

The Role of Primary Androgen Deprivation Therapy in Localized Prostate Cancer

(2009) Yu-Ning Wong et al.   EUROPEAN UROLOGY

Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort

(2009) Andrew J. Vickers et al.   EUROPEAN UROLOGY

Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era

(2009) Andrew J. Stephenson et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer

(2009) Laurence Klotz et al.   JOURNAL OF CLINICAL ONCOLOGY

Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer

(2009) N. L. Keating et al.   JNCI-Journal of the National Cancer Institute

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

(2009) Howard I Scher et al.   LANCET ONCOLOGY

Mortality Results from a Randomized Prostate-Cancer Screening Trial

(2009) Gerald L. Andriole et al.   NEW ENGLAND JOURNAL OF MEDICINE

Screening for Prostate Cancer — The Controversy That Refuses to Die

(2009) Michael J. Barry   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Screening and Prostate-Cancer Mortality in a Randomized European Study

(2009) Fritz H. Schröder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?

(2008) Florian R. Schroeck et al.   BJU INTERNATIONAL

The role of systemic cytotoxic therapy for prostate cancer

(2008) Sam S. Chang et al.   BJU INTERNATIONAL

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

(2008) Joel B. Nelson et al.   CANCER

Active surveillance for early-stage prostate cancer

(2008) Marc A. Dall'Era et al.   CANCER

Is Prostate-Specific Antigen Velocity Selective for Clinically Significant Prostate Cancer in Screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam)

(2008) Tineke Wolters et al.   EUROPEAN UROLOGY

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

(2008) Nicholas D. James et al.   EUROPEAN UROLOGY

Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer

(2008) Susan Halabi et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Population

(2008) David Ulmert et al.   JOURNAL OF CLINICAL ONCOLOGY

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY

What are the Factors Associated With Short Prostate Specific Antigen Doubling Time After Radical Prostatectomy? A Report From the SEARCH Database Group

(2008) Anna E. Teeter et al.   JOURNAL OF UROLOGY

Risk Stratification for Biochemical Recurrence in Men With Positive Surgical Margins or Extracapsular Disease After Radical Prostatectomy: Results From the SEARCH Database

(2008) Jayakrishnan Jayachandran et al.   JOURNAL OF UROLOGY

Percent Tumor Involvement and Risk of Biochemical Progression After Radical Prostatectomy

(2008) Edward N. Rampersaud et al.   JOURNAL OF UROLOGY

Optimal timing of chemotherapy in androgen independent prostate cancer

(2008) Ian D. Schnadig et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Effect of DNA Methylation on Identification of Aggressive Prostate Cancer

(2008) Joshi J. Alumkal et al.   UROLOGY

Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression

(2008) Marc A Dall'Era et al.   Nature clinical practice. Urology

EAU Guidelines on Prostate Cancer

(2007) Axel Heidenreich et al.   EUROPEAN UROLOGY

Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study

(2007) M.R. Smith et al.   JOURNAL OF UROLOGY